{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:16:24Z","timestamp":1790039784693,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.vaccine.2012.06.013","type":"journal-article","created":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T07:54:46Z","timestamp":1340006086000},"page":"5215-5221","source":"Crossref","is-referenced-by-count":39,"title":["Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines"],"prefix":"10.1016","volume":"30","author":[{"given":"Joseph","family":"Monsonego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Zerat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Syrj\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Zerat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Halfon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.06.013_bib0005","series-title":"GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10","author":"Ferlay","year":"2010"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0010","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"De Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0015","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ejca.2009.07.019","article-title":"HPV infection in Europe","volume":"45","author":"De Vuyst","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0025","series-title":"Le cancer du col de l\u2019uterus en France. Etat des lieux en 2010","author":"Institut National du Cancer","year":"2010"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0030","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ijc.25726","article-title":"Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study","volume":"129","author":"Monsonego","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0035","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1386-6532(09)70007-1","article-title":"Analytical characterization of the APTIMA HPV assay","volume":"45","author":"Dockter","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0040","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1054\/bjoc.2001.1845","article-title":"Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women","volume":"84","author":"Clavel","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0045","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/IGC.0b013e31821dd3b2","article-title":"Prevalence of human papillomavirus infection in women in Portugal: the CLEOPATRE Portugal study","volume":"21","author":"Pista","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0050","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0055","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/jmv.21910","article-title":"Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30years of age: an epidemiological observational study","volume":"82","author":"Iftner","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0060","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/ijc.23712","article-title":"Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark","volume":"123","author":"Kjaer","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0065","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jadohealth.2008.07.009","article-title":"Age-specific prevalence of infection with human papillomavirus in females: a global review","volume":"43","author":"Smith","year":"2008","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0070","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/jiq139","article-title":"Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical cancer","volume":"203","author":"Chaturvedi","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jadohealth.2008.07.009","article-title":"Age-specific prevalence of human papillomavirus infection in females: a global review","volume":"43","author":"Smith","year":"2008","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0080","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.bjc.6604162","article-title":"Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening","volume":"98","author":"Coup\u00e9","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0085","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"De Sanjos\u00e9","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0090","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1158\/1055-9965.EPI-08-0180","article-title":"Prevalence of genital human papilloma virus infection and genotypes among young women in Sicily, South Italy","volume":"17","author":"Ammatuna","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00007435-199503000-00008","article-title":"Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study","volume":"22","author":"Karlsson","year":"1995","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/1055-9965.EPI-05-0577","article-title":"Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys","volume":"15","author":"Vaccarella","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1471-2334-10-157","article-title":"Human papillomavirus infection and risk factors in a cohort of Tuscan women aged 18\u201324: results at recruitment","volume":"10","author":"Confortini","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1470-2045(11)70078-X","article-title":"Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study","volume":"12","author":"Kocken","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0115","unstructured":"Joura E, Paavonen J, Ferris D, Sings HL, James M, Haupt RM. Impact of Gardasil\u00ae in women who have undergone definitive therapy. Abstract and poster presented at the 16th international meeting of the European society of gynaecological oncology, Belgrade, Serbia; 11\u201314 October 2009."},{"key":"10.1016\/j.vaccine.2012.06.013_bib0120","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0125","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2165\/10898580-000000000-00000","article-title":"Human papillomavirus vaccines: current status and future prospects","volume":"70","author":"Garland","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vaccine.2006.05.117","article-title":"Chapter 9: clinical applications of HPV testing: a summary of meta-analyses","volume":"24:S3","author":"Arbyn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0135","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/jnci\/djp367","article-title":"Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting","volume":"101","author":"Leinonen","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0140","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0145","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jnci\/djp392","article-title":"A new generation of studies of human papillomavirus DNA testing in cervical cancer screening","volume":"101","author":"Franco","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0150","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","article-title":"Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25years and older: a subanalysis of the ATHENA study","volume":"12","author":"Castle","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0155","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0160","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/ijc.25915","article-title":"EUROGIN 2010 roadmap on cervical cancer prevention","volume":"128","author":"Franceschi","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0165","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/sj.bjc.6604324","article-title":"Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial","volume":"98","author":"Sargent","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0170","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-na\u00efve women aged 16\u201326years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0175","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0180","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1086\/597308","article-title":"Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types","volume":"199","author":"Herrero","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0185","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0190","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0200","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0205","unstructured":"GlaxoSmithKline Clinical Study Register. Studies 580299\/001 and 580299\/007. Available at: http:\/\/download.gsk-clinicalstudyregister.com\/files\/20401.pdf [accessed 24.11.11]."},{"key":"10.1016\/j.vaccine.2012.06.013_bib0210","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1055-9965.EPI-10-1108","article-title":"Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women","volume":"20","author":"Winer","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2012.06.013_bib0215","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/JCM.01743-09","article-title":"Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+\/6+-PCR-enzyme immunoassay in population-based cervical screening","volume":"48","author":"Hesselink","year":"2010","journal-title":"J Clin Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12008523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12008523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T01:40:27Z","timestamp":1561858827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12008523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":43,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0264410X12008523"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.06.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}